Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer

Martin Ries; Fadi Khreish; Guy Berchem; Samer Ezziddin

doi:10.1097/RLU.0000000000002704

Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer

Martin Ries^*, Fadi Khreish, Guy Berchem, Samer Ezziddin

^*Corresponding author for this work

Luxembourg Institute of Health

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.

Original language	English
Pages (from-to)	730-731
Number of pages	2
Journal	Clinical Nuclear Medicine
Volume	44
Issue number	9
DOIs	https://doi.org/10.1097/RLU.0000000000002704
Publication status	Published - 1 Sept 2019

Keywords

Cancer
Nephropathy
Nephrotoxicity
PRLT
PSMA
Prostate
Radioligand
Renal function

Access to Document

10.1097/RLU.0000000000002704

Cite this

@article{d704a6bff35d48379783e1e8753c7b43,

title = "Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer",

abstract = "Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.",

keywords = "Cancer, Nephropathy, Nephrotoxicity, PRLT, PSMA, Prostate, Radioligand, Renal function",

author = "Martin Ries and Fadi Khreish and Guy Berchem and Samer Ezziddin",

year = "2019",

month = sep,

day = "1",

doi = "10.1097/RLU.0000000000002704",

language = "English",

volume = "44",

pages = "730--731",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "9",

}

TY - JOUR

T1 - Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer

AU - Ries, Martin

AU - Khreish, Fadi

AU - Berchem, Guy

AU - Ezziddin, Samer

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.

AB - Radioligand therapy targeting prostate specific membrane antigen (PSMA-RLT) is becoming increasingly important in palliative care of metastasized castration resistant prostate cancer (mCRPC) as a highly effective and low toxicity therapy option. In addition to its overexpression in prostate cancer cells, PSMA is also physiologically expressed in the kidneys which is raising concerns over dose related nephrotoxicity of PSMA-RLT. We describe potential positive short-term effects of PSMA-RLT on renal function with marked recovery of a pretreatment compromised kidney.

KW - Cancer

KW - Nephropathy

KW - Nephrotoxicity

KW - PRLT

KW - PSMA

KW - Prostate

KW - Radioligand

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=85070872262&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002704

DO - 10.1097/RLU.0000000000002704

M3 - Article

C2 - 31283606

AN - SCOPUS:85070872262

SN - 0363-9762

VL - 44

SP - 730

EP - 731

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 9

ER -

Recovery of renal function under PSMA mediated radioligand therapy of advanced metastasized castration resistant prostate cancer

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this